Dechra Pharmaceuticals (DPH) spent most of the first half integrating its €135m (£110m) Eurovet acquisition. That should ultimately mean cost savings totalling £4m through the rationalisation of different manufacturing sites. However, Dechra's performance will be weighted to the second half of the year, as it deals with a variety of operational issues in its main business divisions that have arisen from its acquisition strategy.
To continue reading, register today
to enjoy limited access to the following:
- Daily trading news
- Funds coverage
- Features on big investment themes
- Comprehensive companies coverage
- Economic analysis